6.
  
    Loscalzo J, Weinfeld M, Fless G, Scanu A
    
    . Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990; 10(2):240-5.
    
          DOI: 10.1161/01.atv.10.2.240.
    
    
View
   
 
                                          
  7.
  
    Behbodikhah J, Ahmed S, Elyasi A, Kasselman L, Leon J, Glass A
    
    . Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target. Metabolites. 2021; 11(10).
          PMC: 8540246.
    
          DOI: 10.3390/metabo11100690.
    
    
View
   
 
                                          
  8.
  
    Fraley A, Schwartz G, Olsson A, Kinlay S, Szarek M, Rifai N
    
    . Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL.... J Am Coll Cardiol. 2009; 53(23):2186-96.
    
          DOI: 10.1016/j.jacc.2009.02.041.
    
    
View
   
 
                                          
  9.
  
    Gurdasani D, Sjouke B, Tsimikas S, Hovingh G, Luben R, Wainwright N
    
    . Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012; 32(12):3058-65.
          PMC: 4210842.
    
          DOI: 10.1161/ATVBAHA.112.255521.
    
    
View
   
 
                                          
  10.
  
    Landray M, Haynes R, Hopewell J, Parish S, Aung T, Tomson J
    
    . Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371(3):203-12.
    
          DOI: 10.1056/NEJMoa1300955.
    
    
View
   
 
                                          
  11.
  
    Maloberti A, Fabbri S, Colombo V, Gualini E, Monticelli M, Daus F
    
    . Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option. Int J Mol Sci. 2023; 24(1).
          PMC: 9820656.
    
          DOI: 10.3390/ijms24010170.
    
    
View
   
 
                                          
  12.
  
    Willeit P, Ridker P, Nestel P, Simes J, Tonkin A, Pedersen T
    
    . Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018; 392(10155):1311-1320.
    
          DOI: 10.1016/S0140-6736(18)31652-0.
    
    
View
   
 
                                          
  13.
  
    Cho T, Jung Y, Koschinsky M
    
    . Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho/Rho kinase/MYPT1-dependent pathway. J Biol Chem. 2008; 283(45):30503-12.
          PMC: 2662143.
    
          DOI: 10.1074/jbc.M802648200.
    
    
View
   
 
                                          
  14.
  
    Yi C, Junyi G, Fengju L, Qing Z, Jie C
    
    . Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients. Clin Cardiol. 2023; 46(5):512-520.
          PMC: 10189068.
    
          DOI: 10.1002/clc.24003.
    
    
View
   
 
                                          
  15.
  
    Deb A, Caplice N
    
    . Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol. 2004; 27(5):258-64.
          PMC: 6654090.
    
          DOI: 10.1002/clc.4960270503.
    
    
View
   
 
                                          
  16.
  
    Etingin O, Hajjar D, Hajjar K, HARPEL P, Nachman R
    
    . Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem. 1991; 266(4):2459-65.
    
    
    
View
   
 
                                          
  17.
  
    Tzoulaki I, Murray G, Lee A, Rumley A, Lowe G, Fowkes F
    
    . Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007; 28(3):354-62.
    
          DOI: 10.1093/eurheartj/ehl441.
    
    
View
   
 
                                          
  18.
  
    Albers J, Slee A, OBrien K, Robinson J, Kashyap M, Kwiterovich Jr P
    
    . Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013; 62(17):1575-9.
          PMC: 3800510.
    
          DOI: 10.1016/j.jacc.2013.06.051.
    
    
View
   
 
                                          
  19.
  
    Rath M, Niendorf A, Reblin T, Dietel M, Krebber H, Beisiegel U
    
    . Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989; 9(5):579-92.
    
          DOI: 10.1161/01.atv.9.5.579.
    
    
View
   
 
                                          
  20.
  
    Sartipy F, Sigvant B, Lundin F, Wahlberg E
    
    . Ten Year Mortality in Different Peripheral Arterial Disease Stages: A Population Based Observational Study on Outcome. Eur J Vasc Endovasc Surg. 2018; 55(4):529-536.
    
          DOI: 10.1016/j.ejvs.2018.01.019.
    
    
View